How do technical and behavioral factors affect blood biomarker results for depression?
Blood biomarkers—such as brain-derived neurotrophic factor (BDNF), inflammatory markers, and other molecules—are being studied as potential tools for diagnosing or monitoring depression. However, their levels can be influenced by many factors beyond depression itself. Technical factors like when blood is drawn and behavioral factors like smoking or body weight can change biomarker readings. This means that a single biomarker result may not directly reflect depression severity or treatment response. Understanding these influences is key to interpreting research and clinical tests.
What the research says
A large UK Biobank study (N~500,000) systematically examined how technical, demographic, and behavioral factors affect 29 common blood biomarkers 3. Technical factors (e.g., time of blood collection, sample handling) explained 1-6% of biomarker variance, while demographic factors (age, sex) explained 5-15% 3. Behavioral factors had strong effects: body mass index (BMI) and smoking significantly influenced inflammatory markers 3. Temporal factors also mattered—many biomarkers showed diurnal rhythms (e.g., testosterone, triglycerides, immune markers), and inflammatory markers peaked in winter 3. When researchers adjusted for these covariates, associations between biomarkers and major depression were often attenuated or eliminated 3.
Exercise training, a behavioral intervention, can alter depression-related biomarkers. A meta-analysis of 12 randomized controlled trials (757 participants) found that exercise increased circulating BDNF and kynurenine levels, and these changes were linked to reduced depressive symptoms 6. This shows that lifestyle behaviors can directly modify biomarker levels, potentially confounding studies that do not account for exercise habits.
Other research highlights that biomarker levels can vary by depression subtype or context. For example, in perimenopausal women, BDNF levels were positively associated with depression severity, contrary to the typical finding of low BDNF in major depression 7. This suggests that hormonal status and life stage can influence biomarker relationships. Additionally, a study on major depression found that levels of certain biomarkers (TOLLIP, VEGF-a, global DNA methylation) differed between patients and healthy controls, but these differences were independent of childhood adversity—except for SIRT1, which was modulated by parental care quality 8. This indicates that personal history can interact with biomarker expression.
While not directly about biomarkers, a systematic review on psychedelic-assisted therapy highlights the importance of blinding and study design in depression research 1. Open-label studies (where patients know their treatment) can produce biased results, which is relevant because biomarker studies often lack blinding to clinical status. Similarly, a meta-analysis on GDNF in bipolar disorder found extreme heterogeneity and publication bias, cautioning against overinterpreting biomarker findings when variability is high 2.
What to ask your doctor
- What specific blood biomarkers are being measured for my depression, and what technical or behavioral factors could affect those results?
- Should I have blood drawn at a consistent time of day or season to improve reliability?
- How do my lifestyle habits—like smoking, exercise, or body weight—influence the interpretation of my biomarker levels?
- Are there any known interactions between my medications and the biomarkers being tested?
- How do my personal history (e.g., childhood adversity, hormonal status) affect the meaning of biomarker results in my case?
This question is drawn from common patient questions about Psychiatry and answered using cited medical research. We do not provide individualized advice.